Last updated on July 2019

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Generalized Pustular Psoriasis | Erythrodermic Psoriasis
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Present with GPP or EP based on an investigator-confirmed diagnosis and meet the associated criteria
  • GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare (MHLW) at screening and baseline regardless of IL-36 mutation status.
  • EP: Diagnosed to have BSA 80% involvement (with inflammatory erythema) at screening and baseline.
  • Candidates for phototherapy and/or systemic therapy
  • Men must agree to use a reliable method of birth control during the study
  • Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion Criteria:

  • History of drug-induced psoriasis
  • Concurrent or recent use of any biologic agent
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
  • Have previously received ixekizumab
  • Serious disorder or illness other than psoriasis
  • Serious infection within the last 12 weeks
  • Breastfeeding or nursing (lactating) women

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.